Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HAIC + Tislelizumab and Adjuvant Tislelizumab in High-risk HCC
NCT06467799Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Started Sep 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06467799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467799.